In summary, this study has demonstrated the important roles of HDACs in ERMS pathogenesis by characterizing the anti-tumor effects of pan-HDAC inhibitors, trichostatin A and suberoylanilide hydroxamic acid (SAHA), in ERMS in vitro and in vivo. The gene discussed is HDAC9; the disease is neoplasm.